1. Home
  2. PPBT vs BCDA Comparison

PPBT vs BCDA Comparison

Compare PPBT & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PPBT
  • BCDA
  • Stock Information
  • Founded
  • PPBT 2010
  • BCDA N/A
  • Country
  • PPBT Israel
  • BCDA United States
  • Employees
  • PPBT N/A
  • BCDA N/A
  • Industry
  • PPBT Biotechnology: Pharmaceutical Preparations
  • BCDA Biotechnology: Pharmaceutical Preparations
  • Sector
  • PPBT Health Care
  • BCDA Health Care
  • Exchange
  • PPBT Nasdaq
  • BCDA Nasdaq
  • Market Cap
  • PPBT 8.7M
  • BCDA 7.9M
  • IPO Year
  • PPBT N/A
  • BCDA N/A
  • Fundamental
  • Price
  • PPBT $3.19
  • BCDA $2.72
  • Analyst Decision
  • PPBT Strong Buy
  • BCDA Strong Buy
  • Analyst Count
  • PPBT 2
  • BCDA 1
  • Target Price
  • PPBT $126.50
  • BCDA $25.00
  • AVG Volume (30 Days)
  • PPBT 33.7K
  • BCDA 53.2K
  • Earning Date
  • PPBT 03-04-2025
  • BCDA 03-26-2025
  • Dividend Yield
  • PPBT N/A
  • BCDA N/A
  • EPS Growth
  • PPBT N/A
  • BCDA N/A
  • EPS
  • PPBT N/A
  • BCDA N/A
  • Revenue
  • PPBT N/A
  • BCDA $71,000.00
  • Revenue This Year
  • PPBT N/A
  • BCDA N/A
  • Revenue Next Year
  • PPBT N/A
  • BCDA N/A
  • P/E Ratio
  • PPBT N/A
  • BCDA N/A
  • Revenue Growth
  • PPBT N/A
  • BCDA N/A
  • 52 Week Low
  • PPBT $2.00
  • BCDA $1.63
  • 52 Week High
  • PPBT $20.60
  • BCDA $8.85
  • Technical
  • Relative Strength Index (RSI)
  • PPBT 43.64
  • BCDA 64.47
  • Support Level
  • PPBT $2.90
  • BCDA $2.27
  • Resistance Level
  • PPBT $3.37
  • BCDA $2.78
  • Average True Range (ATR)
  • PPBT 0.22
  • BCDA 0.28
  • MACD
  • PPBT -0.01
  • BCDA 0.03
  • Stochastic Oscillator
  • PPBT 46.75
  • BCDA 91.04

About PPBT Purple Biotech Ltd.

Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219 and CM24.

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Share on Social Networks: